Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07825207) titled 'Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms' on Sept. 11.

Study Type: Observational

Primary Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS

Condition: Myelodysplastic Neoplasm Myelodysplastic Syndrome

Intervention: Drug: Eltrombopag (ELT)

Recruitment Status: Not recruiting

Date of First Enrollment: May 1, 2026

Target Sample Size: 100

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07825207

Disclaimer: Curated by HT Syndication....